Abstract:

Objective To investigate the short-term clinical effects of the ranibizumab intravitreal injection on age related macular degeneration macular edema (AMD-ME) and retinal vein occlusion macular edema (RVO-ME)． Design Retrospective case series. Participants 30 patients (30 eyes) with 15 AMD-ME and 15 RVO-ME. Methods All patients received ranibizumab 0.05 ml intravitreal injection, using 1+PRN injection algarism. The follow-up examinations were at 1 day, 1 month after the treatment. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were observed and compared between AMD-ME patients and RVO-ME patients before and after injection. Main Outcome Measures BCVA, CMT, IOP. Results The BCVA of both AMD-ME group and RVO-ME group improved significantly at 1 day and 1 month after the ranibizumab intravitreal injection (P=0.000, 0.000). The CMT reduced significantly for both group as well (P=0.000, 0.000). The IOP did not change significantly during the treatment (P=0.096, 0.066, 0.213, 0.088, 0.240, 0.337 for different time points). Conclusion Ranibizumab intravitreal injection can reduce macular edema and improve the visual activity in patients with AMD-ME or RVO-ME． The treatment effect was similar for AMD-ME and RVO-ME． (Ophthalmol CHN, 2017, 26: 120-124)
 

Key words: ranibizumab, age-related macular degeneration, retinal vein occlusion, macular edema